Korro Bio Inc. Ordinary Shares KRRO 深 滬
等待開盤 09-30 09:30:00 美东时间
42.80
+2.140
+5.26%
華盛通- 最 高43.00
- 今 開40.83
- 成交量 42.19万股
- 最 低 39.71
- 昨 收 40.66
- 總市值 4.02亿
- 52周最高 98.00
- 市盈率 靜 --
- 換手率 4.49%
- 52周最低 10.29
- 委 比 -37.69%
- 總股本 939.09万
- 歷史最高 2918.50
- 量 比 1.88
- 振 幅 8.09%
- 歷史最低 9.15
- 每 手 1
- 風險率 14.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
09-12 17:27
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
Korro to Participate in Upcoming Investor and Scientific Conferences
<p>Korro Bio, Inc. announced that its management team, including Dr. Ram Aiyar, Dr. Loic Vincent, Vineet Agarwal, and Todd Chappell, will participate in several investor and scientific conferences throughout September 2025. These include Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, Wells Fargo Securities Healthcare Conference, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Confer...
09-02 20:30
HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $90
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and lowers the price target from $100 to $90.
08-13 20:04
Korro Bio Q2 EPS $(2.74) Misses $(2.56) Estimate, Sales $1.460M Beat $508.625K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(2.74) per share which missed the analyst consensus estimate of $(2.56) by 6.86 percent. This is a 12.76 percent decrease over losses of $(2.43) per share from the
08-12 19:06
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
Korro Bio reports progress in Phase 1/2a REWRITE trial for KRRO-110, completing dosing of over 80% of healthy volunteers with no serious adverse events. KRRO-110 received orphan drug designation for Alpha-1 Antitrypsin Deficiency (AATD) from the European Medicines Agency. A development candidate for a rare metabolic disorder is expected by year-end 2025. The company ended Q2 2025 with $119.6 million in cash. Financial results showed increased R&D...
08-12 11:00
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $100 price target.
07-24 18:11
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
<p>Korro Bio announced that its investigational medicine KRRO-110 has received orphan drug designation from the European Medicines Agency for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). This designation follows the U.S. FDA's orphan drug designation in March 2025. KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical study, with interim data expected in the second half of 2025. The medicine, designed to edit RNA and...
07-21 12:00
Novo Nordisk focused on biotech deals for cardiometabolic indications
In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has no plans to pursue deals with biotechs in other indications. "We want to be...
06-18 05:37
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 10.9% to $0.67 durin...
05-28 05:06
